GIG HARBOR, Wash., May 14, 2026 (GLOBE NEWSWIRE) — IP Strategy Holdings, Inc. (Nasdaq: IPST) (the “Company” or “IP Strategy”) today announced that it received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) dated May 11, 2026 stating that the Nasdaq Hearing Panel (the “Panel”) has determined the Company has regained compliance with Nasdaq’s continued listing standards, including the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The Company will be subject to a Mandatory Panel Monitor for a period of one year from the date of the Panel’s determination pursuant to Nasdaq Rule 5815(d)(4)(B). The Company views the Panel’s determination as an important step in maintaining its Nasdaq listing and continued engagement with the investment community. About IP Strategy IP Strategy Holdings, Inc. (Nasdaq:...

Board-approved Vocal transactions expected to increase Creatd’s ownership from approximately 20% to 51% Annual meeting record date updated to May 26, 2026; virtual shareholder meeting will be scheduled for June 25, 2026 Vocal 3.0 remains on track as Creatd advances its SEC re-registration, corporate reorganization, and planned uplisting strategy NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) — Creatd, Inc. (OTCQB: CRTD) (“Creatd” or the “Company”) today announced two corporate updates related to its broader reorganization and planned uplisting strategy. First, both the Company’s Board of Directors and the requisite shareholders of Vocal, Inc. (“Vocal”) have approved a targeted equity realignment and repurchase initiative, designed to restore Creatd’s majority ownership of Vocal. Second, the Company announced updated dates for its upcoming...

Company selected as Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Award Winner PARAMUS, NJ, May 14, 2026 (GLOBE NEWSWIRE) — Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs), announces that it has been named a double winner of the 2026 GHP Magazine Healthcare & Pharmaceutical Awards as both the Best Pediatric Lysosomal Storage Disease Therapeutics 2026 – USA and the Rare Neurodegenerative Disease Drug Development Excellence Award 2026 – USA awards recipient. “While current treatments have pushed care forward for lysosomal storage disorders, children and their families still face a significant daily treatment burden,”...

Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) — Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate. Curanex is advancing Phyto-N toward a planned Investigational New Drug (“IND”) submission to the U.S. Food and Drug Administration...

SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that the financial advisors of Fifteen:22 Financial Partners have joined LPL Financial’s broker-dealer and Registered Investment Advisor (RIA) platform. The team reported serving approximately $380 million in advisory, brokerage and retirement plan assets* and joins LPL from Nations Financial Group. Based in Kansas, Fifteen:22 Financial Partners is comprised of managing partners Douglas Bennett, Nicholas Bennett, Van Schaffer, Malcolm Ong, Brent Hoffman and Douglas Stephens, bringing together more than 120 years of combined industry experience. Founded more than 35 years ago, the firm was built on a legacy of deep client relationships and has grown through multigenerational referrals and a commitment to personalized, long-term financial guidance. Fifteen:22...

Or Yehuda, Israel, May 14, 2026 (GLOBE NEWSWIRE) — Formula Systems (1985) Ltd. (Nasdaq and TASE: FORTY) (“Formula” or the “Company”), a global information technology group engaged, through its subsidiaries and affiliates, in providing software consulting services and computer-based business solutions and developing proprietary software products, today announced that its board of directors has approved the distribution of a special cash dividend, based on Formula’s results for 2025, including, in particular, the completion of the acquisition of Sapiens by Advent, of $13.045 per share, or approximately $200.0 million in total. The dividend will be paid on June 4, 2026 to all of the Company’s shareholders of record at the close of trading on the Nasdaq Global Select Market (or the Tel-Aviv Stock Exchange, as appropriate) on May 25,...